

INFORMAZIONI PERSONALI

Nome DANIELE CALISTRI
Indirizzo VIA RONCO N.4, 47034 FORLIMPOPOLI, ITALIA
Telefono
E-mail danielecalistri@gmail.it
PEC daniele.calistri@biologo.onb.it
Nazionalità Italiana

Codice fiscale CLSDNL66S22G713D

ESPERIENZA LAVORATIVA

- Date (da – a) Luglio 2016-attuale
- Nome e indirizzo del datore di lavoro Istituto Romagnolo per lo Studio e la Cura dei Tumori (IRST), Meldola, Forlì
- Tipo di azienda o settore Ricerca Oncologica
- Tipo di impiego Dirigente biologo, posizione E1 del CCN sanità privata.
- Principali mansioni e responsabilità Responsabile SS Diagnostica Molecolare Avanzata e Predittiva

- Date (da – a) Luglio 2014-dicembre 2017
- Nome e indirizzo del datore di lavoro Istituto Romagnolo per lo Studio e la Cura dei Tumori (IRST), Meldola, Forlì
- Tipo di azienda o settore Ricerca Oncologica
- Tipo di impiego Dirigente biologo, posizione E1 del CCN sanità privata.
- Principali mansioni e responsabilità Direttore ff SC Laboratorio di Bioscienze

- Date (da – a) Maggio 2010-Giugno 2014
- Nome e indirizzo del datore di lavoro Istituto Romagnolo per lo Studio e la Cura dei Tumori (IRST), Meldola, Forlì
- Tipo di azienda o settore Ricerca Oncologica
- Tipo di impiego Dirigente biologo, posizione E1 del CCN sanità privata.
- Principali mansioni e responsabilità Responsabile Gestionale del Laboratorio di Bioscienze

- Date (da – a) Marzo 2007-Aprile 2010
- Nome e indirizzo del datore di lavoro Istituto Romagnolo per lo Studio e la Cura dei Tumori (IRST), Meldola, Forlì
- Tipo di azienda o settore Ricerca Oncologica
- Tipo di impiego Dirigente biologo, posizione E1 del CCN sanità privata.
- Principali mansioni e responsabilità Responsabile del Settore di Biologia Molecolare

- Date (da – a) Maggio 1996-febbraio 2007
- Nome e indirizzo del datore di lavoro Div. Oncologia medica, Osp. Morgagni-Pierantoni, Forlì
- Tipo di azienda o settore Ricerca Oncologica
- Tipo di impiego Ricercatore
- Principali mansioni e responsabilità Responsabile del Settore di Biologia Molecolare

ISTRUZIONE E FORMAZIONE

- Date (da – a) Novembre 1992-febbraio 1996
- Nome e tipo di istituto di istruzione o formazione Università degli Studi di Pavia
- Principali materie / abilità professionali oggetto dello studio Genetica e biologia molecolare
- Qualifica conseguita Dottorato di ricerca in Scienze Genetiche (genetica e biologia molecolare)
- Date (da – a) Novembre 1985-dicembre 1991
- Nome e tipo di istituto di istruzione o formazione Università degli Studi di Firenze
- Principali materie / abilità professionali oggetto dello studio Biologia, biologia molecolare
- Qualifica conseguita Laurea in Scienze Biologiche

CAPACITÀ E COMPETENZE

PERSONALI

MADRELINGUA **ITALIANA**

ALTRE LINGUA

- Capacità di lettura buono
- Capacità di scrittura buono
- Capacità di espressione orale discreto

- Capacità di lettura discreto
- Capacità di scrittura discreto
- Capacità di espressione orale discreto

CAPACITÀ E COMPETENZE ORGANIZZATIVE

Sviluppo e coordinamento di attività di Diagnostica Biomolecolare.
Identificazione ed ottenimento di risorse per la gestione di tali attività. Provata capacità di diventare centro di riferimento per tali attività e attrazione di risorse.
Sviluppo e coordinamento di controlli di qualità multicentrici per test molecolari.
Sviluppo e coordinamento di attività di raccolta e stoccaggio campioni biologici.
Sviluppo e coordinamento di progetti di ricerca multicentrici.
Sviluppo e coordinamento di unità di bioinformatica.
Sviluppo e coordinamento di database oncologici/molecolari nazionali.
Sviluppo e validazione di test diagnostico-molecolari oggetto di brevetto.

CAPACITÀ E COMPETENZE TECNICHE

TECNICHE DI LABORATORIO DI BIOLOGIA MOLECOLARE. ANALISI DI ACIDI NUCLEICI E PROTEINE TRAMITE TECNICHE DI BIOLOGIA MOLECOLARE QUALI: PCR, REAL-TIME PCR, MICRORRAYS, SEQUENZIAMENTO, NEXT GENERATION SEQUENCING, ANALISI DELLO STATO DI METILAZIONE DEL DNA, ANALISI DI FRAMMENTI CON SISTEMI ELETTROFORETICI A CAPILLARE E GEL, ESTRAZIONE ACIDI NUCLEICI, PROTEINE, BLOTTING, ECC.

OTTIMA CONOSCENZA DEI SISTEMI INFORMATICI (OSX, LINUX, WINDOWS).

OTTIMA CONOSCENZA DELLE RISORSE DISPONIBILI ONLINE PER LE RICERCHE E L'ANALISI DI SEQUENZE DI DNA, RNA E PROTEINE. BUONA CONOSCENZA DI BIOINFORMATICA.

ULTERIORI INFORMAZIONI

Autore di articoli scientifici pubblicati su riviste scientifiche internazionali.

Autore di brevetti.

Autore di capitoli di libri scientifici.

Membro INCa, Insitute nationale du cancer, Program for Translational Cancer Research – PRT-K, 2017-2018

Valutatore ISS controlli di qualità test genetici 2917-2021

ORCID ID: 0000-0002-5064-2023

RESEARCH ID: K-5788-2016

SCOPUS ID: 55924598400

H Index: 30

ALLEGATI

PUBBLICAZIONI, BREVETTI E CAPITOLI LIBRI

Forlì, 08/03/2021


Daniele Calistri

Il sottoscritto è a conoscenza che, ai sensi dell'art.76 DPR 28/12/2000 n.445, le dichiarazioni mendaci, la falsità negli atti e l'uso di atti falsi sono puniti ai sensi del codice penale e delle leggi speciali. Inoltre, il sottoscritto autorizza al trattamento dei dati personali, secondo quanto previsto dal D. lgs. 196/03.

PUBBLICAZIONI

Come primo/ultimo autore e/o corresponding author

1. **Calistri D**, Presciuttini S, Buonsanti G, Radice P, Gazzoli I, Pensotti V, Sala P, Eboli M, Andreola S, Pierotti MA, Bertario L, Ranzani GN. Microsatellite instability and risk assessment in colorectal cancer patients with features suggestive of cancer predisposition: correlation with DNA mismatch repair gene mutations. *Int J Cancer (Pred Oncol)* 89:87-91, 2000.
2. **Calistri D**, Barzanti F, Dal Susino M, Fedriga R, Saragoni L, Bernardi L, Ricotti L, Zoli W. Correlation between p53 gene mutations and p53 protein accumulation evaluated by different methodologies. *J Biol Marker and Hom Agents* 14:120-127, 2000.
3. Rengucci C, Maiolo P, Saragoni L, Zoli W, Amadori D, **Calistri D**. Multiple detection of genetic alterations in tumors and stool. *Clin Cancer Res* 7: 590-593, 2001.
4. Casadei S, Cortesi L, Pensotti V, Radice P, Pierotti M, Amadori D, **Calistri D**. Detection of germline *BRCA1* mutations by Multiple-Dye Cleavase Fragment Length Polymorphism (MDCFLP) method. *Br J Cancer* 85: 845-849, 2001.
5. Fedriga R, Gunelli R, Nanni O, Bacci F, Amadori D, **Calistri D**. Telomerase activity detected by Quantitative assay in bladder carcinoma and exfoliated cells in urine. *Neoplasia* 3: 446-450, 2001.
6. Casadei S, Falcini F, Naldoni C, Nanni O, Amadori D, **Calistri D**. Population-based screening for hereditary breast cancer in a region of north-central Italy. *Int. J. Mol. Med.* 10: 299-305, 2002.
7. **Calistri D**, Rengucci C, Bocchini R, Saragoni L, Zoli W, Amadori D. Fecal multiple molecular tests to detect colorectal cancer in stool. *Clin Gastroenterol Hepatol*, 1: 377-383, 2003.
8. Sanchini MA, Bravaccini S, Medri L, Gunelli R, Baccarani PC, Monti F, Ravaioli A, Nanni O, Amadori D, **Calistri D**. Urine telomerase, an important marker in the diagnosis of bladder cancer. *Neoplasia* 6:234-239, 2004.
9. **Calistri D**, Rengucci C, Lattuneddu A, Francioni G, Polifemo AM, Nanni O, Saragoni L, Monti F, Ravaioli A, Zoli W, Amadori D. Detection of Colorectal Cancer by a Quantitative Fluorescence Determination of DNA Amplification in Stool. *Neoplasia* 6:536-540, 2004.
10. **Calistri D**, Seymour I, Rengucci C, Lattuneddu A, Polifemo AM, Monti F, Saragoni S, Amadori A. Mutation Analysis of p53, K-ras and BRAF Genes in Colorectal Cancer Progression. *J Cell Phys* 204:484-488, 2005.
11. Soldateschi D, Bravaccini S, Berti B, Brogi A, Benicchi T, Soldatini C, Medri L, Fabbri F, De Paola F, Amadori D, Volpi A, **Calistri D**. Development and characterization of a monoclonal antibody directed against human telomerase reverse transcriptase (hTERT). *J Biotechnol* 118:370-378, 2005.
12. Sanchini MA, Gunelli R, Nanni O, Bravaccini S, Fabbri C, Sermasi A, Bercovich E, Ravaioli A, Amadori D, **Calistri D**. Relevance of urine telomerase in the diagnosis of bladder cancer. *JAMA* 294:2052-6, 2005.
13. **Calistri D**, Rengucci C, Seymour I, Leopardi E, Truini M, Malacarne D, Castagnola P, Giaretti W. KRAS, p53 and BRAF gene mutations and aneuploidy in sporadic colorectal cancer progression. *Cell Oncol* 28:161-166, 2006.
14. **Calistri D**, Sanchini A, Amadori D, Silvestrini R. Telomerase activity: a molecular marker for early diagnosis of bladder tumor. *Recenti Prog Med* 98:74-78, 2007.
15. Seymour IJ, Casadei S, Zampiga V, Rosato S, Danesi R, Scarpi E, Falcini F, Strada M, Morini N, Naldoni C, Amadori D, **Calistri D**. Results of a population-based screening for hereditary breast cancer in a region of North-Central Italy: contribution of BRCA1/2 germ-line mutations. *Breast Cancer Res Treat.* 112: 343-349, 2008.
16. Seymour IJ, Casadei S, Zampiga V, Rosato S, Danesi R, Falcini F, Strada M, Morini N, Naldoni C, Paradiso A, Tommasi S, Schitulli F, Amadori D, **Calistri D**. Disease family history and modification of breast cancer risk in common BRCA2 variants. *Oncol Rep* 19: 783-786, 2008.
17. **Calistri D**, Rengucci C, Molinari C, Ricci E, Cavargini E, Scarpi E, Milandri GL, Fabbri C, Ravaioli A, Russo A, Amadori D, Silvestrini R. Quantitative fluorescence determination of long fragment DNA in stool as a marker for the early detection of colorectal cancer. *Cell Oncol* 31:11-17, 2009.
18. Molinari C, Iorio P, Medri L, Ballardini M, Guiducci G, Cremonini AM, Cerasoli S, Riccioni L, Faedi M, Mariani GA, Zoli W, Silvestrini R, **Calistri D**. Chromosome 1p and 19q evaluation in low-grade oligodendrogliomas: a descriptive study. *Int J Mol Med* 25:145-51, 2010.
19. **Calistri D**, Rengucci C, Casadei Gardini A, Frassinetti GL, Scarpi E, Zoli W, Falcini F, Silvestrini R, Dino Amadori D. Fecal DNA for Non-Invasive Diagnosis of Colorectal Cancer in iFOBT-positive individuals. *Cancer Epid Biom Prev*, 19(10); 2647-54, 2010.
20. Bravaccini S, Casadio V, Gunelli R, Bucchi L, Zoli W, Amadori D, Silvestrini R, Calistri D. Combining cytology, TRAP assay, and FISH analysis for the detection of bladder cancer in symptomatic patients. *Ann Oncol.* 22:2294-8, 2011.

21. Molinari C, Ballardini M, Teodorani N, Giannini M, Zoli W, Emiliani E, Lucci E, Passardi A, Rosetti P, Saragoni L, Guidoboni M, Amadori D, **Calistri D**. Genomic alterations in rectal tumors and response to neoadjuvant chemoradiotherapy: an exploratory study. *Radiation Oncology*, 6:161, 2011.
22. **Calistri D**, Zampiga Z and Zoli W Characterization of Molecular Alterations of BRCA1/2: Analysis and Interpretation Guidelines. *Current Women`s Health Reviews* 8: 4-11.
23. **Calistri D**, Casadio V, Bravaccini S, Zoli W, Amadori D. Urinary biomarkers of non-muscleinvasive bladder cancer: current status and future potential. *Expert Rev Anticancer Ther* 12:74352, 2012.
24. Pasini A, Paganelli G, Tesei A, Zoli W, Giordano E, **Calistri D**. Specific Biomarkers Are Associated with Docetaxel- and Gemcitabine-Resistant NSCLC Cell Lines. *Translational Oncology* 5:461468, 2012.
25. Molinari C, Casadio V, Foca F, Zingaretti C, Giannini M, Avanzolini A, Lucci E, Saragoni L, Passardi A, Amadori D, **Calistri D**, Zoli W. Gene methylation in rectal cancer: Predictive marker of response to chemoradiotherapy? *J Cell Physiol*. 228:2343-9, 2013.
26. De Maio G, Rengucci C, Zoli W, Zoli W, **Calistri D**. Circulating and stool nucleic acid analysis for colorectal cancer diagnosis. *World Journal of Gastroenterology*, 20:957–967, 2014.
27. Cavallo D, Casadio V, Bravaccini S, Iavicoli S, Pira E, Romano C, Fresegna AM, Maiello R, Ciervo A, Buresti G, Zoli W, Calistri D. Assessment of DNA damage and telomerase activity in exfoliated urinary cells as sensitive and noninvasive biomarkers for early diagnosis of bladder cancer in exworkers of a rubber tyres industry. *Biomed Res Int*. 2014:370907, 2014.
28. Tedaldi G, Danesi R, Zampiga V, Tebaldi M, Bedei L, Zoli W, Amadori A, Falcini F, **Calistri D**. First evidence of a large CHEK2 duplication involved in cancer predisposition in an Italian family with hereditary breast cancer. *BMC Cancer*, 14:478, 2014.
29. Rengucci C, De Maio G, Gardini A, Zucca M, Scarpi E, Zingaretti C, Foschi G, Tumedei M, Molinari C, Saragoni L, Puccetti M, Amadori D, Zoli W, **Calistri D**. Promoter methylation of tumor suppressor genes in pre-neoplastic lesions; potential marker of disease recurrence. *J Exp Clin Cancer Res*. 33(1):65, 2014.
30. Rengucci C, De Maio G, Menghi M, Scarpi E, Guglielmo S, Fusaroli P, Caletti G, Saragoni L, Casadei Gardini A, Zoli W, Falcini F, Amadori D, **Calistri D**. Improved Stool DNA Integrity Method for Early Colorectal Cancer Diagnosis. *Cancer Epidemiol Biomarkers Prev*. 23:2553-60, 2014.
31. Molinari C, Salvi S, Foca F, Teodorani N, Saragoni L, Puccetti M, Passardi A, Tamberi S, Avanzolini A, Lucci E, **Calistri D**. miR-17-92a-1 cluster host gene (MIR17HG) evaluation and response to neoadjuvant chemoradiotherapy in rectal cancer. *Onco Targets Ther*. 9:2735-42, 2016.
32. Zampiga V, Danesi R, Tedaldi G, Tebaldi M, Cangini I, Pirini F, Pittureri C, Amaducci E, Guidi L, Faedi M, Amadori D, Falcini F, **Calistri D**. Multiple primary tumors in a family with Li-Fraumeni syndrome with a TP53 germline mutation identified by next-generation sequencing. *Int J Biol Markers*. doi: 10.5301/ijbm.5000227, 2016
33. De Maio G, Zama E, Rengucci C, **Calistri D**. What influences preneoplastic colorectal lesion recurrence? *8:12406-12416*, 2017.
34. Casadio V, Salvi S, Martignano F, Gunelli R, Ravaioli S, **Calistri D**. Cell-Free DNA Integrity Analysis in Urine Samples. *J Vis Exp*. doi: 10.3791/55049, 2017.
35. Tedaldi G, Tebaldi M, Zampiga V, Danesi R, Arcangeli V, Ravegnani M, Cangini I, Pirini F, Petracci E, Rocca A, Falcini F, Amadori D, **Calistri D**. Multiple-gene panel analysis in a case series of 255 women with hereditary breast and ovarian cancer. *Oncotarget*. 8:47064-47075, 2017.
36. Rengucci C, De Maio G, Menghi M, **Calistri D**. Stool DNA Integrity Method for Colorectal Cancer Detection. *Methods Mol Biol*. 1765:193-202, 2018
37. Molinari C, Abou Khouzam R, Salvi S, Rossi T, Ranzani GN, **Calistri D**. Detection of a CDH1 Rare Transcript Variant in Fresh-frozen Gastric Cancer Tissues by Chip-based Digital PCR. *J Vis Exp*. Feb 5;(132), 2018.
38. Tedaldi G, Pirini F, Tebaldi M, Zampiga V, Cangini I, Danesi R, Arcangeli V, Ravegnani M, Abou Khouzam R, Molinari C, Oliveira C, Morgagni P, Saragoni L, Bencivenga M, Ulivi P, Amadori D, Martinelli G, Falcini F, Ranzani GN, **Calistri D**. Multigene Panel Testing Increases the Number of Loci Associated with Gastric Cancer Predisposition. *Cancers (Basel)*. 2019 Sep 11;11(9). pii: E1340.
39. Pirini F, Tedaldi G, Danesi R, Cangini I, Tumedei MM, Ferrari A, Vitali S, De Maio G, Terragna C, Solli V, Tebaldi M, Puccetti M, Zampiga V, Ravegnani M, Ulivi P, Falcini F, Martinelli G, **Calistri D**. Identification of a novel large EPCAM-MSH2 duplication, concurrently with LOHs in chromosome 20 and X, in a family with Lynch syndrome. *Int J Colorectal Dis*. 2019
40. Tedaldi G, Tebaldi M, Zampiga V, Cangini I, Pirini F, Ferracci E, Danesi R, Arcangeli V, Ravegnani M, Martinelli G, Falcini F, Ulivi P, **Calistri D**. Male Breast Cancer: Results of the Application of Multigene Panel Testing to an Italian Cohort of Patients. *Diagnostics (Basel)*. 10(5):E269, 2020.

41. Rengucci C, De Maio G, Menghi M, Benzi F, **Calistri D**. Evaluation of Colorectal Cancer Risk and Prevalence by Stool DNA Integrity Detection. *J Vis Exp*. 2020 Jun 8;(160).

Come co-autore

1. Ranzani GN, Luinetti O, Padovan LS, **Calistri D**, Renault B, Burrel M, Amadori D, Fiocca R, Solcia E.
p53 gene mutations and protein nuclear accumulation are early events in intestinal type gastric cancer but late events in diffuse type. *Cancer Epidemiol Biomarkers Prev* 4(3):223-31, 1995.
2. Solcia E, Fiocca R, Luinetti O, Villani L, Padovan L, **Calistri D**, Ranzani GN, Chiaravalli A, Capella C. Intestinal and diffuse gastric cancers arise in a different background of Helicobacter pylori gastritis through different gene involvement. *Am J Surg Pathol* 20(Suppl. 1):18-22, 1996.
3. Renault B, **Calistri D**, Buonsanti G, Nanni O, Amadori D, Ranzani GN. Microsatellite instability and mutations of p53 and TGF-beta RII genes in gastric cancer. *Hum Genet* 98(5):601-7, 1996.
4. Buonsanti G, **Calistri D**, Padovan L, Luinetti O, Fiocca R, Solcia E, Ranzani GN. Microsatellite instability in intestinal- and diffuse-type gastric carcinoma. *J Pathol* 182(2):167-73, 1997.
5. Pensotti V, Radice P, Presciuttini S, **Calistri D**, Gazzoli I, Grimalt Perez A, Mondini P, Buonsanti G, Sala P, Rossetti C, Ranzani GN, Bertario L, Pierotti MA. Mean age of tumor onset in hereditary nonpolyposis colorectal cancer (HNPCC) families correlates with the presence of mutations in DNA mismatch repair genes. *Genes Chromosomes Cancer* 19(3):135-42, 1997.
6. Maltoni M, Volpi A, Nanni O, Bajorko P, Belletti E, Vecchi AM, Liverani M, Danesi S, **Calistri D**, Ricotti L, Amadori D. Gastric cancer: epidemiologic and biological aspects. *Forum (Genova)* 8(2):199-207, 1998.
7. Fedriga R, **Calistri D**, Nanni O, Cortesi L, Saragoni L, Amadori D. Relation between food habits and p53 mutational spectrum in gastric cancer patients. *Int J Oncol* 17:127-133, 2000.
8. Ulivi P, Zoli W, Medri L, Amadori D, Paragoni L, Barbanti F, **Calistri D**, Silvestrini R. c-kit and SCF expression in normal and tumor breast tissue. *Breast Cancer Res Treat.* 83:33-42, 2004.
9. Tommasi S, Crapolicchio A, Lacalamita R, Bruno M, Monaco A, Petroni S, Schittulli F, Longo S, Digennaro M, **Calistri D**, Mangia A, Paradiso A. BRCA1 mutations and polymorphisms in a hospitalbased consecutive series of breast cancer patients from Apulia, Italy. *Mutat Res*, 578:395-405, 2005.
10. Bravaccini S, Sanchini MA, Amadori A, Medri L, Saragoni L, **Calistri D**, Monti F, Volpi A, Amadori D. Potential of telomerase expression and activity in cervical specimens as a diagnostic tool. *J Clin Pathol* 58:911-4, 2005.
11. Mercatali L, Valenti V, **Calistri D**, Calpona S, Rosti G, Folli S, Gaudio M, Frassinetti GL, Amadori D, Flamini E. RT-PCR determination of maspin and mammaglobin B in peripheral blood of healthy donors and breast cancer patients. *Ann Oncol.* 17:424-8, 2006.
12. Ulivi P, Zoli W, Calistri D, Fabbri F, Mengozzi M, Amadori D. p16INK4A and CDH13 Hypermethylation in Tumor and Serum of Non-Small Cell Lung Cancer Patients. *J Cell Phys* 206:611-615, 2006.
13. Flamini E, Mercatali L, Nanni O, **Calistri D**, Nunziatini R, Zoli W, Rosetti P, Gardini N, Lattuneddu A, Verdecchia GM, Amadori D. Free DNA and carcinoembryonic antigen serum levels: an important combination for diagnosis of colorectal cancer. *Clin Cancer Res* 12:6985-8, 2006.
14. Tommasi S, Fedele V, Lacalamita R, Bruno M, Schittulli F, Ginzinger D, Scott G, Eppenberger-Castori S, **Calistri D**, Casadei S, Seymour I, Longo S, Giannelli G, Pilato B, Simone G, Benz CC, Paradiso A. 655Val and 1170Pro ERBB2 SNPs in familial breast cancer risk and BRCA1 alterations. *Cell Oncol* 29:241-8, 2007.
15. Bravaccini S, Sanchini MA, Granato AM, Gunelli R, Nanni O, Amadori D, **Calistri D**, Silvestrini R. Urine telomerase activity for the detection of bladder cancer in females. *J Urol* 178:57-61, 2007.
16. Bravaccini S, Casadio V, Amadori D, **Calistri D**, Silvestrini R. The current role of telomerase in the diagnosis of bladder cancer. *Indian J Urol* 25:40-46, 2009.
17. Paradiso A, Mangia A, Orlando C, Verderio P, Belfiglio M, Marchetti A, Bertario L, Chiappetta G, Gion M, Tonini GP, Podo F, Vocaturo A, Silvestrini R, Romani M, Belloni E, Cavallo D, Ulivi P, Tommasi S, Steffan A, Russo A, Alessio M, **Calistri D**, Zancan M, Parrela P, Brogginini M, Giuseppe A, Buttitta F, Finocchiaro G, Mazzocco K, Veronesi G, Landuzzi L, Benevolo M, Mariani L, De Marco F, Venuti A, Giannelli G, Quaranta M, Trojano V. The Integrated Oncology Program of the Italian Ministry of Health. Analytical and clinical validation of new biomarkers for early diagnosis: network, resources, methodology, quality control, and data analysis. *Int J Biol Markers* 24:119-29; 2009.

18. Casadio V, Bravaccini S, Gunelli R, Nanni O, Zoli W, Amadori D, **Calistri D**, Silvestrini R. Accuracy of urine telomerase activity to detect bladder cancer in symptomatic patients. *Int J Biol Markers*. 24:253-7, 2009.
19. Mercatali L, Ibrahim T, Sacanna E, Flamini E, Scarpi E, **Calistri D**, Ricci M, Serra P, Ricci R, Zoli W, Kang Y, Amadori D. Bone metastases detection by circulating biomarkers: OPG and RANK-L. *Int J Oncol*. 39:255-6, 2011.
20. Molinari C, Medri L, Follo MY, Piazzini M, Mariani GA, Calistri D, Cocco L. PI-PLC β 1 gene copy number alterations in breast cancer. *Oncol Rep*. 27:403-8, 2012.
21. Ulivi P, Capelli L, Valgiusti M, Zoli W, Scarpi E, Chiadini E, Rosetti P, Bravaccini S, **Calistri D**, Saragoni L, Casadei Gardini A, Ragazzini A, Frassinetti GL, Amadori D, Passardi A. Predictive role of multiple gene alterations in response to cetuximab in metastatic colorectal cancer: a single center study. *J Transl Med* 10:87, 2012.
22. Ulivi P, Zoli W, Chiadini E, Capelli L, Candoli P, **Calistri D**, Silvestrini R, Puccetti M. EGFR and K-ras mutations in cytologic samples from fine-needle aspirates in NSCLC patients. *Eur Respir J*. 2012 Jul;40(1):267-9.
23. Gardini A, Saragoni L, La Barba G, Serra L, **Calistri D**, Ulivi P, Casadei A, Frassinetti GL, Garcea D. Challenge in differential diagnosis of a liver mass histologically defined as a metastatic lesion from an occult primary intestinal tumour. The importance of clinical findings and the limitations of histology and molecular profiles. A case report. *Pathologica* 104(4):177-81, 2012.
24. Pasini A, Iorio P, Bianchi E, Cerasoli S, Cremonini AM, Faedi M, Guarnieri C, Guiducci G, Riccioni L, Molinari C, Rengucci C, **Calistri D**, Giordano E. LOH 19q indicates shorter disease progression-free interval in low-grade oligodendrogliomas with EMP3 methylation. *Oncol Rep*. 28(6):2271-7, 2012.
25. Casadio V, **Calistri D**, Tebaldi M, Bravaccini S, Gunelli R, Martorana G, Bertaccini A, Serra L, Scarpi E, Amadori D, Silvestrini R, Zoli W. Urine Cell-Free DNA integrity as a marker for early bladder cancer diagnosis: Preliminary data. *Urol Oncol*. 2012.
26. Casadio V, **Calistri D**, Salvi S, Gunelli R, Carretta E, Amadori D, Silvestrini R, Zoli W. Urine cellfree DNA integrity as a marker for early prostate cancer diagnosis: a pilot study. *Biomed Res Int*. 2013:270457, 2013.
27. Ulivi P, Puccetti M, Capelli L, Chiadini E, Bravaccini S, **Calistri D**, Zoli W, Amadori D, Candoli P. Molecular determinations of EGFR and EML4-ALK on a single slide of NSCLC tissue. *J Clin Pathol*. 66(8):708-10, 2013.
28. Casadio V, Molinari C, **Calistri D**, Tebaldi M, Gunelli R, Serra L, Falcini F, Zingaretti C, Silvestrini R, Amadori D, Zoli W. DNA Methylation profiles as predictors of recurrence in non muscle invasive bladder cancer: an MS-MLPA approach. *J Exp Clin Cancer Res*. 32:94, 2013.
29. Ulivi P, Zoli W, Capelli L, Chiadini E, Calistri D, Amadori D. Target therapy in NSCLC patients: Relevant clinical agents and tumour molecular characterisation. *Mol Clin Oncol*. 1:575-581, 2013.
30. Salvi S, **Calistri D**, Gurioli G, Carretta E, Serra L, Gunelli R, Zoli W, Casadio V. Copy Number Analysis of 24 Oncogenes: MDM4 Identified as a Putative Marker for Low Recurrence Risk in Non Muscle Invasive Bladder Cancer. *Int J Mol Sci*. 15:12458-68, 2014.
31. Marisi G, Passardi A, **Calistri D**, Zoli W, Amadori D, Ulivi P. Discrepancies between VEGF -1154 G>A Polymorphism Analysis Performed in Peripheral Blood Samples and FFPE Tissue. *Int J Mol Sci*. 15:13333-43, 2014.
32. Scarpi E, **Calistri D**, Klepstad P, Kaasa S, Skorpen F, Habberstad R, Nanni O, Amadori D, Maltoni M. Oncologist Clinical and Genetic Factors Related to Cancer-Induced Bone Pain and Bone Pain Relief. *Oncologist* 19:1276-83, 2014.
33. Ulivi P, Delmonte A, Chiadini E, **Calistri D**, Papi M, Mariotti M, Verlicchi A, Ragazzini A, Capelli L, Gamboni A, Puccetti M, Dubini A, Burgio MA, Casanova C, Crinò L, Amadori D, Dazzi C. Gene Mutation Analysis in EGFR Wild Type NSCLC Responsive to Erlotinib: Are There Features to Guide Patient Selection? *Int J Mol Sci*. 16:747-57, 2014.
34. Chiadini E, Scarpi E, Passardi A, **Calistri D**, Valgiusti M, Saragoni L, Zoli W, Amadori D, Ulivi P. EGFR methylation and outcome of patients with advanced colorectal cancer treated with cetuximab. *Oncol Lett*. 9:1432-1438, 2015.
35. Bravaccini S, Tumedei MM, Ulivi P, Zoli W, **Calistri D**, Candoli P, Amadori D, Puccetti M. ALK translocation detection in non-small cell lung cancer cytological samples obtained by TBNA or EBUS-TBNA. *Cytopathology*. 27:103-107, 2016.
36. Salvi S, Casadio V, Conteduca V, Burgio SL, Menna C, Bianchi E, Rossi L, Carretta E, Masini C, Amadori D, **Calistri D**, Attard G, De Giorgi U. Circulating cell-free AR and CYP17A1 copy number variations may associate with outcome of metastatic castration-resistant prostate cancer patients treated with abiraterone. *Br J Cancer*. 112:1717-24, 2015.

37. Salvi S, Gurioli G, Martignano F, Foca F, Gunelli R, Cicchetti G, De Giorgi U, Zoli W, **Calistri D**, Casadio V. Urine Cell-Free DNA Integrity Analysis for Early Detection of Prostate Cancer Patients. *Dis Markers*. 2015:574120, 2015.
38. Ulivi P, Scarpi E, Passardi A, Marisi G, **Calistri D**, Zoli W, Del Re M, Frassinetti GL, Tassinari D, Tamberi S, Vertogen B, Amadori D. eNOS polymorphisms as predictors of efficacy of bevacizumab-based chemotherapy in metastatic colorectal cancer: data from a randomized clinical trial. *J Transl Med*. 13:258, 2015.
39. Pasini A, Delmonte A, Tesei A, **Calistri D**, Giordano E. Targeting Chromatin-Mediated Transcriptional Control of Gene Expression in Non-Small Cell Lung Cancer Therapy: Preclinical Rationale and Clinical Results. *Drugs*. 75:1757-71, 2015.
40. Ulivi P, Chiadini E, Dazzi C, Dubini A, Costantini M, Medri L, Puccetti M, Capelli L, **Calistri D**, Verlicchi A, Gamboni A, Papi M, Mariotti M, De Luigi N, Scarpi E, Bravaccini S, Turolla GM, Amadori D, Crinò L, Delmonte A. Nonsquamous, Non-Small-Cell Lung Cancer Patients Who Carry a Double Mutation of EGFR, EML4-ALK or KRAS: Frequency, Clinical-Pathological Characteristics, and Response to Therapy. *Clin Lung Cancer*. 15(15):00268-5, 2015.
41. Salvi S, Conteduca V, Gurioli G, **Calistri D**, Casadio V, De Giorgi U. Impact of Candidate Genetic Polymorphisms in Prostate Cancer: An Overview. *Mol Diagn Ther*. 20(1):1-12, 2016.
42. Briigliadori G, Foca F, Dall'Agata M, Rengucci C, Melegari E, Cerasoli S, Amadori D, **Calistri D**, Faedi M. Defining the cutoff value of MGMT gene promoter methylation and its predictive capacity in glioblastoma. *J Neurooncol*. 128:333-9, 2016.
43. Bonanno L, Calabrese F, Nardo G, **Calistri D**, Tebaldi M, Tedaldi G, Polo V, Vuljan S, Favaretto A, Conte P, Amadori A, Rea F, Indraccolo S. Morphological and genetic heterogeneity in multifocal lung adenocarcinoma: The case of a never-smoker woman. *Lung Cancer*. 96:52-5, 2016.
44. Salvi S, Casadio V, Conteduca V, Lolli C, Gurioli G, Martignano F, Schepisi G, Testoni S, Scarpi E, Amadori D, **Calistri D**, Attard G, Giorgi U. Circulating AR copy number and outcome to enzalutamide in docetaxel-treated metastatic castration-resistant prostate cancer. *Oncotarget*. 7(25):37839-37845, 2016.
45. Capelli L, Petracci E, Quagliuolo V, Saragoni L, Colombo P, Morgagni P, **Calistri D**, Tomezzoli A, Di Cosmo M, Roviello F, Vindigni C, Coniglio A, Villanacci V, Catarci M, Coppola L, Alfieri S, Ricci R, Capella C, Rausei S, Gulino D, Amadori D, Ulivi P; Italian Gastric Cancer Research Group (GIRCG). Gastric GISTs: Analysis of c-Kit, PDGFRA and BRAF mutations in relation to prognosis and clinical pathological characteristics of patients - A GIRCG study. *Eur J Surg Oncol*. 42:120614, 2016.
46. Gurioli G, Salvi S, Martignano F, Foca F, Gunelli R, Costantini M, Cicchetti G, De Giorgi U, Sbarba PD, **Calistri D**, Casadio V. Methylation pattern analysis in prostate cancer tissue: identification of biomarkers using an MS-MLPA approach. *J Transl Med*. 14:249, 2016.
47. Martignano F, Gurioli G, Salvi S, **Calistri D**, Costantini M, Gunelli R, De Giorgi U, Foca F, Casadio V. GSTP1 Methylation and Protein Expression in Prostate Cancer: Diagnostic Implications. *Dis Markers*. 2016:4358292, 2016.
48. Salvi S, Casadio V, Conteduca V, Lolli C, Gurioli G, Martignano F, Schepisi G, Testoni S, Scarpi E, Amadori D, **Calistri D**, Attard G, De Giorgi U. Circulating AR copy number and outcome to enzalutamide in docetaxel-treated metastatic castration-resistant prostate cancer. *Oncotarget*. 7:37839-37845, 2016.
49. Salvi S, Gurioli G, De Giorgi U, Conteduca V, Tedaldi G, **Calistri D**, Casadio V. Cell-free DNA as a diagnostic marker for cancer: current insights. *Onco Targets Ther*. 9:6549-6559, 2016.
50. Canale M, Petracci E, Delmonte A, Chiadini E, Dazzi C, Papi M, Capelli L, Casanova C, De Luigi N, Mariotti M, Gamboni A, Chiari R, Bennati C, **Calistri D**, Ludovini V, Crinò L, Amadori D, Ulivi P. Impact of TP53 Mutations on Outcome in EGFR-Mutated Patients Treated with First-Line Tyrosine Kinase Inhibitors. *Clin Cancer Res*. 23:2195-2202, 2016
51. Salvi S, Martignano F, Molinari C, Gurioli G, **Calistri D**, De Giorgi U, Conteduca V, Casadio V. The potential use of urine cell free DNA as a marker for cancer. *Expert Rev Mol Diagn*. 16:12831290, 2016.
52. Maltoni R, Casadio V, Ravaioli S, Foca F, Tumedei MM, Salvi S, Martignano F, **Calistri D**, Rocca A, Schirone A, Amadori D, Bravaccini S. Cell-free DNA detected by "liquid biopsy" as a potential prognostic biomarker in early breast cancer. *Oncotarget*. 8:16642-16649, 2017.
53. Bonelli MA, Digiacomio G, Fumarola C, Alfieri R, Quaini F, Falco A, Madeddu D, La Monica S, Cretella D, Ravelli A, Ulivi P, Tebaldi M, **Calistri D**, Delmonte A, Ampollini L, Carbognani P, Tiseo M, Cavazzoni A, Petronini PG. Combined Inhibition of CDK4/6 and PI3K/AKT/mTOR Pathways Induces a Synergistic Anti-Tumor Effect in Malignant Pleural Mesothelioma Cells. *Neoplasia*. 19:637-648, 2017.
54. Ulivi P, Scarpi E, Chiadini E, Marisi G, Valgiusti M, Capelli L, Casadei Gardini A, Monti M, Ruscelli S, Frassinetti GL, **Calistri D**, Amadori D, Passardi A. Right- vs. Left-Sided Metastatic Colorectal

- Cancer: Differences in Tumor Biology and Bevacizumab Efficacy. *Int J Mol Sci.* 18(6). pii: E1240, 2017.
55. Zuntini R, Cortesi L, **Calistri D**, Pippucci T, Martelli PL, Casadio R, Capizzi E, Santini D, Miccoli S, Medici V, Danesi R, Marchi I, Zampiga V, Fiorentino M, Ferrari S, Turchetti D. BRCA1 p.His1673del is a pathogenic mutation associated with a predominant ovarian cancer phenotype. *Oncotarget.* 8:22640-22648, 2017.
 56. Abou Khouzam R, Molinari C, Salvi S, Marabelli M, Molinaro V, Orioli D, Saragoni L, Morgagni P, **Calistri D**, Ranzani GN. Digital PCR identifies changes in CDH1 (E-cadherin) transcription pattern in intestinal-type gastric cancer. *Oncotarget.* 8:18811-18820, 2017.
 57. Salvi S, Conteduca V, Martignano F, Gurioli G, **Calistri D**, Casadio V. Serum and Plasma Copy Number Detection Using Real-time PCR. *J Vis Exp.* 2017
 58. Silvestri V, Rizzolo P, Zelli V, Valentini V, Zanna I, Bianchi S, Tibiletti MG, Varesco L, Russo A, Tommasi S, Coppa A, Capalbo C, **Calistri D**, Viel A, Cortesi L, Manoukian S, Bonanni B, Montagna M, Palli D, Radice P, Peterlongo P, Ottini L. A possible role of FANCM mutations in male breast cancer susceptibility: Results from a multicenter study in Italy. *Breast.* 38:92-97, 2018
 59. Ulivi P, Canale M, Passardi A, Marisi G, Valgiusti M, Frassinetti GL, **Calistri D**, Amadori D, Scarpi E. Circulating Plasma Levels of miR-20b, miR-29b and miR-155 as Predictors of Bevacizumab Efficacy in Patients with Metastatic Colorectal Cancer. *Int J Mol Sci.*19(1). pii: E307, 2018
 60. De Matteis S, Molinari C, Abbati G, Rossi T, Napolitano R, Ghetti M, Di Rorà AGL, Musuraca G, Lucchesi A, Rigolin GM, Cuneo A, **Calistri D**, Fattori PP, Bonafè M, Martinelli G. Immunosuppressive Treg cells acquire the phenotype of effector-T cells in chronic lymphocytic leukemia patients. *J Transl Med.* 16(1):172, 2018.
 61. Salvi S, Casadio V, Martignano F, Gurioli G, Tumedei MM, **Calistri D**, Gunelli R, Costantini M. Carcinosarcoma of the prostate: case report with molecular and histological characterization. *Int J Biol Markers.* Aug 12:1724600818791463, 2018
 62. Mori G, Rampelli S, Orena BS, Rengucci C, De Maio G, Barbieri G, Passardi A, Casadei Gardini A, Frassinetti GL, Gaiarsa S, Albertini AM, Ranzani GN, **Calistri D**, Pasca MR. Shifts of Faecal Microbiota During Sporadic Colorectal Carcinogenesis. *Sci Rep.* 8(1):10329, 2018
 63. Chiadini E, Canale M, Delmonte A, Dazzi C, Casanova C, Capelli L, Mariotti M, Papi M, Gamboni A, Puccetti M, Bravaccini S, Dubini A, **Calistri D**, Crinò L, Ulivi P, Frequency of actionable alterations in epidermal growth factor receptor (*EGFR*) wild type non-small cell lung cancer: experience of the Wide Catchment Area of Romagna (AVR). *J Thorac Dis* 10: 4858-4864, 2018
 64. Rizzolo P, Silvestri V, Bucalo A, Zelli V, Valentini V, Catucci I, Zanna I, Masala G, Bianchi S, Spinelli AM, Tommasi S, Tibiletti MG, Russo A, Varesco L, Coppa A, **Calistri D**, Cortesi L, Viel A, Bonanni B, Azzollini J, Manoukian S, Montagna M, Radice P, Palli D, Peterlongo P, Ottini L. Contribution of *MUTYH* Variants to Male Breast Cancer Risk: Results From a Multicenter Study in Italy. *Front Oncol.* 8:583, 2018
 65. Rizzolo P, Zelli V, Silvestri V, Valentini V, Zanna I, Bianchi S, Masala G, Spinelli AM, Tibiletti MG, Russo A, Varesco L, Giannini G, Capalbo C, **Calistri D**, Cortesi L, Viel A, Bonanni B, Azzollini J, Manoukian S, Montagna M, Peterlongo P, Radice P, Palli D, Ottini L. Insight into genetic susceptibility to male breast cancer by multigene panel testing: Results from a multicenter study in Italy. *Int J Cancer.* 145:390-400, 2019
 66. Dhieb D, Belguith I, Capelli L, Chiadini E, Canale M, Bravaccini S, Yangui I, Boudawara O, Jlidi R, Boudawara T, Calistri D, Keskes LA, Ulivi P. Analysis of Genetic Alterations in Tunisian Patients with Lung Adenocarcinoma. *Cells.*;8(6), 2019
 67. Rossi T, Tedaldi G, Petracci E, Abou Khouzam R, Ranzani GN, Morgagni P, Saragoni L, Monti M, Calistri D, Ulivi P, Molinari C. E-cadherin Downregulation and microRNAs in Sporadic Intestinal-Type Gastric Cancer. *Int J Mol Sci.* 20(18). pii: E4452, 2019.
 68. Figlioli G, Kvist A, Tham E, Soukupova J, Kleiblova P, Muranen TA, Andrieu N, Azzollini J, Balmaña J, Barroso A, Benítez J, Bertelsen B, Blanco A, Bonanni B, Borg Å, Brunet J, **Calistri D**, Calvello M, Chvojka S, Cortesi L, Darder E, Del Valle J, Diez O; ENIGMA Consortium, EonMarchais S, Fostira F; GENESIS Study Collaborators, Gensini F, Houdayer C, Janatova M, Kiiski JI, Konstantopoulou I, Kubelka-Sabit K, Lázaro C, Lesueur F, Manoukian S, Marcinkute R, Mickys U, Moncoutier V; SWE-BRCA Group, Myszk A, Nguyen-Dumont T, Nielsen FC, Norvilas R, Olah E, Osorio A, Papi L, Peissel B, Peixoto A, Plaseska-Karanfilska D, Póczy T, Rossing M, Rudaitis V, Santamariña M, Santos C, Smichkoska S, Southey MC, Stoppa-Lyonnet D, Teixeira M, Törnngren T, Toss A, Urioste M, Vega A, Vlckova Z, Yannoukakos D, Zampiga V, Kleibl Z, Radice P, Nevanlinna H, Ehrencrona H, Janavicius R, Peterlongo P. The Spectrum of *FANCM* Protein Truncating Variants in European Breast Cancer Cases. *Cancers (Basel).* 12 pii:E292, 2020

69. .Paolisso P, Saturi G, Foà A, Saponara M, Nannini M, Pantaleo MA, Leone O, Turchetti D, **Calistri D**, Savini C, Pacini D, Pizzi C, Galiè N. Primary malignant pericardial tumour in Lynch syndrome *BMC Cancer*. 20(1):191,2020
70. Zamagni A, Pasini A, Pirini F, Ravaioli S, Giordano E, Tesei A, **Calistri D**, Ulivi P, Fabbri F, Foca F, Delmonte A, Molinari C CDKN1A upregulation and cisplatin-pemetrexed resistance in non-small cell lung cancer cells. *Int J Oncol*. ;56(6):1574-1584,2020
71. Pirini F, Pasini L, Tedaldi G, Scarpi E, Marisi G, Molinari C, **Calistri D**, Passardi A, Ulivi P. Instability of Non-Standard Microsatellites in Relation to Prognosis in Metastatic Colorectal Cancer Patients. *Int J Mol Sci*. 21(10): E3532, 2020
72. Napolitano R, De Matteis S, Carloni S, Bruno S, Abbati G, Capelli L, Ghetti M, Bochicchio MT, Liverani C, Mercatali L, **Calistri D**, Cuneo A, Menon K, Musuraca G, Martinelli G, Simonetti G. Kevetrin induces apoptosis in TP53 wild-type and mutant acute myeloid leukemia cells. *Oncol Rep*. 44(4):1561-1573, 2020
73. Fumagalli C, Guerini-Rocco E, Buttitta F, Iapicca P, You W, Mauri M, Felicioni L, Troncone G, Malapelle U, Scarpa A, Zamboni G, **Calistri D**, Barberis M, Marchetti A. Reliability and reproducibility among different platforms for tumour BRCA testing in ovarian cancer: a study of the Italian NGS Network. *J Clin Pathol*. Oct 5 jclinpath-2020-206800, 2020
74. Ferrari A, Ghelli L, Luserna Di Rora A, Domizio C, Papayannidis C, Simonetti G, Maria HernándezRivas J, Rondoni M, Giglio F, Abruzzese E, Imovilli A, Iacobucci I, **Calistri D**, Martinelli G. Rearrangements of ATP5L-KMT2A in acute lymphoblastic leukaemia. *Br J Haematol*. 2020 Dec
13. doi: 10.1111/bjh.1726

1. BREVETTI

1. DNA analysis of BRCA1 gene. Patent n. MI99A 000512. 5748meur.
2. Molecular early diagnosis of colorectal cancer by quantitative evaluation of DNA extracted from stool.. Patent n. MI2003A 000434. 6988meur.
3. "Method for the identification of colorectal tumors" European patent n. 1601792, 08/12/2010.
4. "Method for the identification of colorectal tumors" United States patent n. 8343722B2, 01/01/2013.
5. "Method for the identification of colorectal tumors" Canada patent n. 59692-NP, 10/01/2013.

CAPITOLI DI LIBRI

1. Manuale di semeiotica e diagnostica oncologica. Ed. Dino Amadori, Rita Golfieri, Sandro Grilli. "Semeiotica biomolecolare" Sandro Grilli, **Daniele Calistri**. Poletto editore, Milano, 2003.
2. Terapia molecolare in oncologia. Ed. Dino Amadori, Carlo Croce. "Determinanti biomolecolari del cancro" **Daniele Calistri**, Sandro Grilli. Poletto editore, Milano, 2004.
3. Terapia molecolare in oncologia. Ed. Dino Amadori, Carlo Croce. "Bersagli molecolari della terapia" Sandro Grilli, **Daniele Calistri**. Poletto editore, Milano, 2004.

Autore di molte decine di abstract presentati a congressi nazionali ed internazionali come poster o comunicazione orale.